Sunday, November 22, 2026

Novavax Stock Bullish Momentum With A 20% Rise So Far On Monday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Novavax Stock Bullish Momentum With A 20% Rise So Far On Monday

(VIANEWS) - Shares of Novavax (NASDAQ: NVAX) rose by a staggering 20.06% to $8.68 at 11:23 EST on Monday, following the last session's upward trend. NASDAQ is dropping 0.1% to $13,646.60, after three consecutive sessions in a row of losses. This seems, at the moment, a somewhat bearish trend exchanging session today.

Novavax's last close was $7.23, 90.4% under its 52-week high of $75.33.

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-13.8.

Volatility

Novavax's last week, last month's, and last quarter's current intraday variation average was a negative 0.70%, a negative 0.19%, and a positive 4.55%.

Novavax's highest amplitude of average volatility was 2.31% (last week), 3.26% (last month), and 4.55% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Novavax's EBITDA is 0.68.

More news about Novavax (NVAX).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 10 Jul 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.